Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, my colleagues were diligently roaming the halls of Congress yesterday, talking to senators about their thoughts on RFK Jr. Read on to hear what the lawmakers said.
The need-to-know this morning
- Merck acquired a preclinical, oral GLP-1 obesity drug candidate from China’s Hansoh Pharma. Shares of Viking Therapeutics fell on the Merck announcement. Viking is developing its own obesity drugs and has been viewed as a potential acquisition target by pharma companies, including Merck.
RFK Jr. builds Senate support, as FDA deputy commissioner prepares to leave
Robert F. Kennedy Jr. is meeting with nearly two dozen Republican senators this week in a bid to clinch their votes for his confirmation as HHS secretary. STAT approached more than a dozen of those senators yesterday, and none said they’d oppose his nomination outright, though a few said they have concerns about his views on vaccines.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
